allogeneic BCMA CAR-expressing iNKT / Shanghai Pharma - LARVOL DELTA

Novel allogeneic BCMA CAR-expressing iNKT cells with PD1 deletion demonstrate superior tumor control in a multiple myeloma preclinical model (ASH 2025) - "Background : Two BCMA-directed CAR-T cell products, Idecabtagene vicleucel (ide-cel) and Ciltacabtageneautoleucel (cilta-cel), have received FDA approval for use in patients with relapsed/refractory multiplemyeloma (R/R MM) and demonstrated outstanding benefit. We are advancing a novel allogeneic CAR-iNKT cell therapy by integrating our proprietaryPD-1 intracellular retention technology to boost the efficacy of adoptive cell treatment. Leveraging aniNKT platform naturally devoid of alloreactivity, we enable rapid engineering and expansion of an "off-the-shelf" CAR product. Additionally, the inherent capabilities of iNKT cells, such as bone marrow homingand BCMA targeting, reinforced by CD1d and NK receptor-ligand interactions, offer unique advantages.We believe this approach could deliver significant benefits to patients with R/R MM, surpassing theefficacy of existing therapies."

Preclinical • Graft versus Host Disease • Hematological Malignancies • Immunology • Multiple Myeloma • Oncology • PD-1